## SEVERITY OF ILLNESS

### CRITICALLY ILL COVID-19 PATIENTS

**Hospitalized, ICU-based**
- Patients requiring mechanical ventilatory support or vasopressor/inotropic support

**Chloroquine or Hydroxychloroquine** is **not** recommended for the treatment of COVID-19.

**Lopinavir/ritonavir** is **not** recommended for the treatment of COVID-19.

**Remdesivir** is **not** recommended outside of approved clinical trials.

**Interferon IV/SC** is **not** recommended for the treatment of COVID-19.

**Ribavirin/Interferon (Inhaled)** is **not** recommended outside of approved clinical trials.

### ANTIVIRAL THERAPY

<table>
<thead>
<tr>
<th>Severe Illness</th>
<th>Chloroquine or Hydroxychloroquine</th>
<th>Lopinavir/ritonavir</th>
<th>Remdesivir</th>
<th>Interferon IV/SC</th>
<th>Ribavirin/Interferon (Inhaled)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> demonstrated</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
</tr>
</tbody>
</table>

**Remdesivir** has not demonstrated benefit in survival, progression to ventilation or length of hospital stay and remains uncertain with respect to shortening time to recovery by 5 days. The World Health Organization (WHO) has issued a conditional recommendation against the use of remdesivir in hospitalized COVID-19 patients. Further evaluation in approved clinical trials is strongly encouraged.

If remdesivir is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values and preferences is necessary, as it is not considered standard of care. Furthermore, it should be restricted to hospitalized patients requiring supplemental oxygen but not requiring non-invasive or invasive mechanical ventilation.

| Interferon IV/SC | **not** recommended outside of approved clinical trials |

### MILDLY ILL COVID-19 PATIENTS

**Ambulatory, outpatient, long-term care**
- Patients who do not require supplemental oxygen, intravenous fluids, or other physiological support

**Chloroquine or Hydroxychloroquine** is **not** recommended for the treatment of COVID-19.

**Lopinavir/ritonavir** is **not** recommended for the treatment of COVID-19.

**Remdesivir** is **not** recommended outside of approved clinical trials.

**Interferon IV/SC** is **not** recommended for the treatment of COVID-19.

**Ribavirin/Interferon (Inhaled)** is **not** recommended outside of approved clinical trials.

### ANTIVIRAL THERAPY

<table>
<thead>
<tr>
<th>Severe Illness</th>
<th>Chloroquine or Hydroxychloroquine</th>
<th>Lopinavir/ritonavir</th>
<th>Remdesivir</th>
<th>Interferon IV/SC</th>
<th>Ribavirin/Interferon (Inhaled)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> demonstrated</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
</tr>
</tbody>
</table>

### ANTIBACTERIAL THERAPY

<table>
<thead>
<tr>
<th>Severe Illness</th>
<th>Chloroquine or Hydroxychloroquine</th>
<th>Lopinavir/ritonavir</th>
<th>Remdesivir</th>
<th>Interferon IV/SC</th>
<th>Ribavirin/Interferon (Inhaled)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> demonstrated</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
</tr>
</tbody>
</table>

**Antibacterial therapy** is **not** routinely recommended outside of approved clinical trials unless other indications justify its use (e.g., suspected bacterial co-infection in COVID-19 positive patients).

### IMMUNOMODULATORY THERAPY

<table>
<thead>
<tr>
<th>Severe Illness</th>
<th>Chloroquine or Hydroxychloroquine</th>
<th>Lopinavir/ritonavir</th>
<th>Remdesivir</th>
<th>Interferon IV/SC</th>
<th>Ribavirin/Interferon (Inhaled)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> demonstrated</td>
<td><strong>not</strong> recommended</td>
<td><strong>not</strong> recommended</td>
</tr>
</tbody>
</table>

**Corticosteroids** are **not** recommended outside of approved clinical trials unless otherwise indicated.

**Biologics/Small molecules (Tocilizumab, Sarilumab, Anakinra, Baricitinib)** are **not** recommended outside of approved clinical trials.

### OTHER THERAPEUTICS

**Enoxaparin 30 mg SC q12h** is suggested for VTE prophylaxis.

**ACE inhibitors and ARBs** should not be discontinued solely on the basis of COVID-19.

**NSAIDs** should not be discontinued solely on the basis of COVID-19.

### SUMMARY

This document is dynamic and addresses key therapeutic areas of concern for clinicians. The complete and most up-to-date version of the guidelines is available at [http://www.pcc.ca/health-professionals/clinical-resources/covid-19-care/clinical-care/treatments](http://www.pcc.ca/health-professionals/clinical-resources/covid-19-care/clinical-care/treatments).

---

* e.g., asthma exacerbation, refractory septic shock, history of chronic steroid use, obstetric use for fetal lung maturation

* The Remdesivir Review and Advisory Working Group evaluates the evidence and utility of remdesivir, provides recommendations on its use, and determines its allocation within the province.